Skip to main content

Table 1 Characteristics of the included studies

From: Role of the intestinal microbiome in colorectal cancer surgery outcomes

Authors, year Study design No. of patients1 Tumor stage Microbiome type, tissue sample Detection method Bacteria2 Short-term surgical outcomes Long-term oncological outcomes Mean (SD) or median (range) follow-up Adjustments on covariates
Flanagan et al., 2014 Cohort 32 Dukes staging A-D MAM, tumor Bacterial DNA, qPCR Fusobacterium nucleatum Not reported • Overall survival 5 years Not specified
Flemer et al., 2018 Cohort 47 AJCC
I-IV
MAM, tumor Bacterial DNA, V3-V4 16S rRNA CAG Not reported • Overall survival 1371 days
(67–1792 days)
Tumor stage, age, gender, treatment with chemotherapy and/or radiotherapy and cancer site
Kosumi et al., 2018 Cohort 1313 AJCC
I-IV
MAM, tumor Bacterial DNA, qPCR Bifidobacterium Not reported • Cancer-specific mortality
• Overall mortality
14.3 years
(10–18.3 years)
Microsatellite instability status, CpG island methylator phenotype, long-interspersed nucleotide element-1 methylation, KRAS, BRAF, and PIK3CA mutations.
Mima et al., 2016 Cohort 1069 AJCC
I-IV
MAM, tumor Bacterial DNA, qPCR Fusobacterium nucleatum Not reported • Cancer-specific mortality
• Overall mortality
10.7 years
(7–15.8 years)
Age, sex, year of diagnosis, family history of colorectal carcinoma in a first-degree relative, tumor location, microsatellite instability (MSI, mismatch repair deficiency), CpG island methylator phenotype (CIMP), KRAS, BRAF, and PIK3CA mutations, and LINE-1 hypomethylation (low-level methylation).
Van Praagh et al., 2017 Case-control 118 Not specified3 MAM, anastomosis Bacterial DNA, V3-V4 16S rRNA All Anastomotic leakage Not reported Not reported Not specified
Wei et al., 2016 Cohort 180 AJCC
I-IV
MAM, tumor Bacterial DNA, V4 16S rRNA All Not reported • Overall survival
• Disease-free survival
47 months
(36–59 months)
Not specified
Yan et al., 2017 Cohort 208 AJCC
III-IV
MAM, tumor Bacterial DNA, qPCR Fusobacterium nucleatum Not reported • Cancer-specific survival
• Disease-free survival
Not reported Not specified
Yu et al., 2017 Cohort 296 AJCC
II-III
MAM, tumor Bacterial DNA, qPCR Fusobacterium nucleatum Not reported • Recurrence-free survival Not reported Not specified
  1. AJCC, American Joint Committee on Cancer; MAM, mucosa-associated microbiome; CAG, tissue-associated microbial co-abundance groups; qPCR, quantitative polymerase chain reaction
  2. 1Patients included in the analysis of the microbiome and its association with short- or long-term outcomes
  3. 2Bacteria analyzed for an association with short- or long-term outcomes
  4. 3The study also included 6 non-oncological patients